IntraLase kept at outperform by RBC

RBC Capital Markets analyst Phil Nalbone maintained IntraLase Corp. at outperform, speculative risk, with a 12-month price target of $25 after the stock fell more than 7.5% on Monday on concerns about a slowing U.S. Lasik (laser vision correction surgery) market. Nalbone believes worries about Intralase's third-quarter and full-year results are unfounded. IntraLase is less dependent on Lasik industry growth than on displacing the use of microkeratomes for corneal flap creations. Nalbone forecasts IntraLase sales of $31 million for the quarter and $128.9 million for the year. Shares of the Irvine, Calif.-based vision laser products company were up 61 cents, or 3.32%, at $18.98. (Nasdaq: ILSE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.